FeversNCT00596375
Lidocaine Lubricant in Pediatric Urethral Catheterization
A study testing Lubricant Instillation and Lidocaine Lubricant in people with Fevers and Pain, run by Children's Healthcare of Atlanta at 1 site in United States.
Trial summary
In Emergency Departments (ED) across the nation there is renewed interest in finding ways to alleviate the pain and discomfort associated with many of the procedures that children must undergo. Read more about this study
- Who is it for?
- Ages 2 months to 2 years
- What is being tested?
- Lubricant Instillation and Lidocaine Lubricant
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 47 participants
- Where
- 1 siteUnited States
- Study dates
- Aug 2006to Mar 2007
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 months to 2 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Febrile patients aged 2 months to 2 years receiving urethral catheterization to obtain sterile urine for microbiologic and chemistry testing will be eligible to participate. Our study will be limited to children presenting with fever secondary to an unknown source, as ED triage protocol requires the administration of non-steroidal analgesic to treat fever.
Who cannot join
- The physician determines the patient is in need of immediate treatment or catheterization
- Patients have a history of genitourinary abnormalities
- Patients have had a previous catheterization
- Primary caregiver has limited English proficiency
- Patients with a history of genitourinary abnormalities
- Patients with history of prior catheterization are excluded from enrollment
Trial locations and contacts
1 site in 1 country.
United States1 site
Children's Healthcare of Atlanta
Atlanta, Georgia, 30322
About this study
Official title: Lidocaine Lubricant Use as an Anesthetic Agent in Emergency Room Urethral Catheterization
In Emergency Departments (ED) across the nation there is renewed interest in finding ways to alleviate the pain and discomfort associated with many of the procedures that children must undergo. In a policy by the American Academy of Pediatrics, a nationally recognized advocate for children, physicians are urged to advocate for child-specific research in pain management and the effective use of pain medication to ensure compassionate and competent management of pain. (AAP Statement, 2001) Pediatric urethral catheterizations are one such procedure in which children experience significant pain.(11) In present care, children over 2 months of age do not routinely receive intervention for urethral catheterization related anxiety and pain, and, anecdotal reports suggest that most require physical restraint to complete the procedure. Lidocaine is an anesthetic agent that provides relief from pain during many commonly performed ED procedures. Intraurethral Lidocaine has been shown to decrease pain associated with urethral catheter placement in cystograms, however, Lidocaine is not routinely used for urethral catheterizations in the CHOA ED.
This study aims to investigate the potential use of Lidocaine as an anesthetic agent during urethral catheterization of children. Recently, two specific studies were performed investigating the use of Lidocaine to decrease discomfort associated with urethral catheterization. Using the strengths of both previously published studies, our study will use Lidocaine both topically and instilled into the urethra. Investigators plan to perform a prospective three-arm double-blinded randomized clinical trial investigating the effectiveness of Lidocaine jelly as a analgesic when used as a lubricant for urinary catheterization. Investigators aim to demonstrate that Lidocaine used as a lubricant anesthetic for urethral catheterization will provide a safe, time-efficient, and relatively easy way to decrease pediatric pain in the emergency department setting.
Read the detailed description
In Emergency Departments (ED) across the nation there is renewed interest in finding ways to alleviate the pain and discomfort associated with many of the procedures that children must undergo. Children's memory and reaction to negative experiences in the care of medical professionals has led to many changes in procedural pain management (4). One noxious procedure that continues to be performed in the ED without the use of anesthetic agents is urethral catheterization (11). In a policy by the American Academy of Pediatrics, a nationally recognized advocate for children, physicians are urged to advocate for child-specific research in pain management and the effective use of pain medication to ensure compassionate and competent management of pain. (AAP Statement, 2001)
Pediatric urethral catheterizations are one such procedure in which children experience significant pain. (11) The Children's Healthcare of Atlanta (CHOA) ED at Egleston performs an average of greater than 150 pediatric urethral catheterizations per month. This procedure is performed in most cases where children under 6 months of age present with unexplained fever. Also, divisional guidelines call for urethral catheterization for urinanalysis and urine culture on all uncircumcised boys under the age of 1 and all girls under the age of 2 who present with unexplained temperature above 39.5 degrees. In a previous Friends funded clinical trial, ED investigators studied sucrose use in children under 2 months of age which was shown to decrease urethral catheterization discomfort. As such, this has become routine care in the ED. (REF; for a review of sucrose for pediatric pain, see 6) In present care, children over 2 months of age do not routinely receive intervention for urethral catheterization related anxiety and pain, and, anecdotal reports suggest that most require physical restraint to complete the procedure.
Lidocaine is an anesthetic agent that provides relief from pain during many commonly performed ED procedures. Examples of present Lidocaine use in the ED are laceration repair, abscess drainage, and lumbar puncture. Given the anxiety, discomfort, and pain associated with urethral catheterizations (1, 2, 3, 4), Lidocaine has begun to be used clinically in this arena. Intraurethral Lidocaine has been shown to decrease pain associated with urethral catheter placement in cystograms, however, Lidocaine is not routinely used for catheter placement to obtain urine in the CHOA ED.
Recently, two specific studies were performed investigating the use of Lidocaine to decrease discomfort associated with urethral catheterization. The first published study supports the use of intraurethral Lidocaine for catheterization.(5) In this investigation, Lidocaine was repeatedly instilled into the urethra of ten 4- to 11-year-old patients for approximately 10 minutes prior to a scheduled cystogram. Patients in this study indicated significantly less pain with Lidocaine as a lubricant when compared to those who received sterile lubricant jelly. However, the placement of a catheter for cystogram requires the catheter to be in place for the duration of the procedure (10 to 15 minutes); whereas catheterization in the ED for urinalysis and urine culture requires catheter placement for a much shorter period of time. The second study, which compared Lidocaine to lubricant jelly used as a topical anesthetic prior to catheterization, found that preverbal patients experienced the same discomfort with or without Lidocaine when evaluated using Face-Legs-Activity-Cry-Consolability (FLACC) scoring.(11) Authors attempted to investigate Lidocaine topically placed at the urethral meatus to provide relief. Although the investigators did not achieve their goal of pain reduction using Lidocaine topically, they did find that the incidence of positive urine culture was similar in both the Lidocaine and placebo groups. Using the strengths of both previously published studies, our study will use Lidocaine both topically and instilled into the urethra.
Medical care professionals are increasing their attention to pain and comfort measures for children undergoing painful procedures in the ED. Pediatric urethral catheterization is one such area that remains unaddressed. The use of Lidocaine as an anesthetic in common ED procedures is well known. Investigation of Lidocaine use as an anesthetic lubricant has been reported twice previously in pediatric literature with contradicting results. After critical appraisal of these studies, our investigators conclude that additional investigation is warranted with the following characteristics: Lidocaine should be placed both topically and instilled into the urethra; Lidocaine should be compared to both routine care and placebo; methodology should include blinded observations; methodology should evaluate pain response utilizing numerous validated tools; and urine should be monitored to evaluate the biological effects of Lidocaine on urine culture results. Investigators aim to demonstrate that Lidocaine used as a lubricant anesthetic for urethral catheterization will provide a safe, time-efficient, and relatively easy way to decrease pediatric pain in the emergency department setting.
Specific Aims \& Hypotheses
SA1: To study the potential use of Lidocaine as an anesthetic agent during urethral catheterization of children presenting to Pediatric Emergency Department.
H1: The use of Lidocaine jelly as a lubricant in urethral catheterizations in pediatric ED patients significantly decreases distress associated with this procedure.
SA2: To determine the average Lidocaine concentration present in urine obtained with Lidocaine jelly used as lubricant during urinary catheterization.
H2: Urine Lidocaine concentrations associated with routine urethral catheterization utilizing intraurethral Lidocaine installation will not approach known bacterial growth-limiting levels.
- Being tested
- Lubricant Instillation, Lidocaine Lubricant
- Keywords
- Lidocaine, Infant, Urinary Catheterization, Emergency Medicine, Analgesia
- Medical subject headings
- Fever, Pain, Agnosia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lubricant InstillationProcedure or surgery
Lubricant jelly instilled in urethra prior to catheterization
Lidocaine LubricantDrug
2% Lidocaine lubricant instillation prior to urethral catheterization
| Study group | Role | What they receive |
|---|---|---|
| Routine Care Group | No intervention | The routine care group will help us to quantify the routine amount of distress associated with catheterization. |
| Lidocaine Group | Experimental | A experimental group will include patients who will have 2% Lidocaine instilled into the urethra prior to catheterization. This group of subjects receiving routine care plus Lidocaine, will be evaluated during each of the four phases of the intervention. Receives: Drug: Lidocaine Lubricant |
| Instillation | Experimental | This group will undergo catheterization utilizing routine care plus lubricant jelly instilled into the urethra. This placebo group will aid in discerning the effects of instillation into the urethra on pain and associated distress. Receives: Procedure: Lubricant Instillation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Modified Behavior Pain Scale
Measured: Procedure (approx. 6 minutes)
Secondary outcomes (2)
Lidocaine Concentration
Measured: Procedure (approx. 6 minutes)
Visual Analog Scale
Measured: Procedure (approx. 6 minutes)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jan 2008 (estimated)
- Study startAug 2006
- Study completionMar 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for FeversStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 47 participants (actual)
Sponsor and investigators
- Lead sponsor
- Children's Healthcare of Atlanta
- Sponsor type
- University, hospital or other
- Collaborators
- Emory University
- Investigators
- Michael Greenwald, MD, Principal investigator, Children's Healthcare of AtlantaPatrick P Mularoni, MD, Study director, Johns Hopkins All Children's Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00596375
- Sponsor's protocol ID
- 06693
- Status last verified
- Dec 2007
- First submitted
- 8 Jan 2008
- Last updated
- 17 Jan 2008
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Jan 2008. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Lidocaine Lubricant Use as an Anesthetic Agent in Emergency Room Urethral Catheterization
- ClinicalTrials.gov ID
- NCT00596375
- Acronym / sponsor ID
- 06693
- Keywords
- Lidocaine, Infant, Urinary Catheterization, Emergency Medicine, Analgesia
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 47 participants (actual)
- Lead sponsor
- Children's Healthcare of AtlantaUniversity, hospital or other
- Collaborators
- Emory University
- Study start
- Aug 2006
- Study completion
- Mar 2007 (actual)
- First posted
- 17 Jan 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In Emergency Departments (ED) across the nation there is renewed interest in finding ways to alleviate the pain and discomfort associated with many of the procedures that children must undergo. In a policy by the American Academy of Pediatrics, a nationally recognized advocate for children, physicians are urged to advocate for child-specific research in pain management and the effective use of pain medication to ensure compassionate and competent management of pain. (AAP Statement, 2001) Pediatric urethral catheterizations are one such procedure in which children experience significant pain.(11) In present care, children over 2 months of age do not routinely receive intervention for urethral catheterization related anxiety and pain, and, anecdotal reports suggest that most require physical restraint to complete the procedure. Lidocaine is an anesthetic agent that provides relief from pain during many commonly performed ED procedures. Intraurethral Lidocaine has been shown to decrease pain associated with urethral catheter placement in cystograms, however, Lidocaine is not routinely used for urethral catheterizations in the CHOA ED.
This study aims to investigate the potential use of Lidocaine as an anesthetic agent during urethral catheterization of children. Recently, two specific studies were performed investigating the use of Lidocaine to decrease discomfort associated with urethral catheterization. Using the strengths of both previously published studies, our study will use Lidocaine both topically and instilled into the urethra. Investigators plan to perform a prospective three-arm double-blinded randomized clinical trial investigating the effectiveness of Lidocaine jelly as a analgesic when used as a lubricant for urinary catheterization. Investigators aim to demonstrate that Lidocaine used as a lubricant anesthetic for urethral catheterization will provide a safe, time-efficient, and relatively easy way to decrease pediatric pain in the emergency department setting.
Detailed description
In Emergency Departments (ED) across the nation there is renewed interest in finding ways to alleviate the pain and discomfort associated with many of the procedures that children must undergo. Children's memory and reaction to negative experiences in the care of medical professionals has led to many changes in procedural pain management (4). One noxious procedure that continues to be performed in the ED without the use of anesthetic agents is urethral catheterization (11). In a policy by the American Academy of Pediatrics, a nationally recognized advocate for children, physicians are urged to advocate for child-specific research in pain management and the effective use of pain medication to ensure compassionate and competent management of pain. (AAP Statement, 2001)
Pediatric urethral catheterizations are one such procedure in which children experience significant pain. (11) The Children's Healthcare of Atlanta (CHOA) ED at Egleston performs an average of greater than 150 pediatric urethral catheterizations per month. This procedure is performed in most cases where children under 6 months of age present with unexplained fever. Also, divisional guidelines call for urethral catheterization for urinanalysis and urine culture on all uncircumcised boys under the age of 1 and all girls under the age of 2 who present with unexplained temperature above 39.5 degrees. In a previous Friends funded clinical trial, ED investigators studied sucrose use in children under 2 months of age which was shown to decrease urethral catheterization discomfort. As such, this has become routine care in the ED. (REF; for a review of sucrose for pediatric pain, see 6) In present care, children over 2 months of age do not routinely receive intervention for urethral catheterization related anxiety and pain, and, anecdotal reports suggest that most require physical restraint to complete the procedure.
Lidocaine is an anesthetic agent that provides relief from pain during many commonly performed ED procedures. Examples of present Lidocaine use in the ED are laceration repair, abscess drainage, and lumbar puncture. Given the anxiety, discomfort, and pain associated with urethral catheterizations (1, 2, 3, 4), Lidocaine has begun to be used clinically in this arena. Intraurethral Lidocaine has been shown to decrease pain associated with urethral catheter placement in cystograms, however, Lidocaine is not routinely used for catheter placement to obtain urine in the CHOA ED.
Recently, two specific studies were performed investigating the use of Lidocaine to decrease discomfort associated with urethral catheterization. The first published study supports the use of intraurethral Lidocaine for catheterization.(5) In this investigation, Lidocaine was repeatedly instilled into the urethra of ten 4- to 11-year-old patients for approximately 10 minutes prior to a scheduled cystogram. Patients in this study indicated significantly less pain with Lidocaine as a lubricant when compared to those who received sterile lubricant jelly. However, the placement of a catheter for cystogram requires the catheter to be in place for the duration of the procedure (10 to 15 minutes); whereas catheterization in the ED for urinalysis and urine culture requires catheter placement for a much shorter period of time. The second study, which compared Lidocaine to lubricant jelly used as a topical anesthetic prior to catheterization, found that preverbal patients experienced the same discomfort with or without Lidocaine when evaluated using Face-Legs-Activity-Cry-Consolability (FLACC) scoring.(11) Authors attempted to investigate Lidocaine topically placed at the urethral meatus to provide relief. Although the investigators did not achieve their goal of pain reduction using Lidocaine topically, they did find that the incidence of positive urine culture was similar in both the Lidocaine and placebo groups. Using the strengths of both previously published studies, our study will use Lidocaine both topically and instilled into the urethra.
Medical care professionals are increasing their attention to pain and comfort measures for children undergoing painful procedures in the ED. Pediatric urethral catheterization is one such area that remains unaddressed. The use of Lidocaine as an anesthetic in common ED procedures is well known. Investigation of Lidocaine use as an anesthetic lubricant has been reported twice previously in pediatric literature with contradicting results. After critical appraisal of these studies, our investigators conclude that additional investigation is warranted with the following characteristics: Lidocaine should be placed both topically and instilled into the urethra; Lidocaine should be compared to both routine care and placebo; methodology should include blinded observations; methodology should evaluate pain response utilizing numerous validated tools; and urine should be monitored to evaluate the biological effects of Lidocaine on urine culture results. Investigators aim to demonstrate that Lidocaine used as a lubricant anesthetic for urethral catheterization will provide a safe, time-efficient, and relatively easy way to decrease pediatric pain in the emergency department setting.
Specific Aims \& Hypotheses
SA1: To study the potential use of Lidocaine as an anesthetic agent during urethral catheterization of children presenting to Pediatric Emergency Department.
H1: The use of Lidocaine jelly as a lubricant in urethral catheterizations in pediatric ED patients significantly decreases distress associated with this procedure.
SA2: To determine the average Lidocaine concentration present in urine obtained with Lidocaine jelly used as lubricant during urinary catheterization.
H2: Urine Lidocaine concentrations associated with routine urethral catheterization utilizing intraurethral Lidocaine installation will not approach known bacterial growth-limiting levels.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Routine Care Group | No intervention | –The routine care group will help us to quantify the routine amount of distress associated with catheterization. |
| Lidocaine Group | Experimental | Drug: Lidocaine LubricantA experimental group will include patients who will have 2% Lidocaine instilled into the urethra prior to catheterization. This group of subjects receiving routine care plus Lidocaine, will be evaluated during each of the four phases of the intervention. |
| Instillation | Experimental | Procedure: Lubricant InstillationThis group will undergo catheterization utilizing routine care plus lubricant jelly instilled into the urethra. This placebo group will aid in discerning the effects of instillation into the urethra on pain and associated distress. |
Who may qualify
- Ages
- 2 months to 2 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (1 listed)
- Febrile patients aged 2 months to 2 years receiving urethral catheterization to obtain sterile urine for microbiologic and chemistry testing will be eligible to participate. Our study will be limited to children presenting with fever secondary to an unknown source, as ED triage protocol requires the administration of non-steroidal analgesic to treat fever.
Key exclusion criteria (6 listed)
- The physician determines the patient is in need of immediate treatment or catheterization
- Patients have a history of genitourinary abnormalities
- Patients have had a previous catheterization
- Primary caregiver has limited English proficiency
- Patients with a history of genitourinary abnormalities
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Lubricant InstillationLubricant jelly instilled in urethra prior to catheterization | Procedure or surgery | Instillation |
| Lidocaine Lubricant2% Lidocaine lubricant instillation prior to urethral catheterization | Drug | Lidocaine Group |
Primary outcome
Modified Behavior Pain Scale
Time frame: Procedure (approx. 6 minutes)
2 secondary outcomes
Lidocaine Concentration
Time frame: Procedure (approx. 6 minutes)
Visual Analog Scale
Time frame: Procedure (approx. 6 minutes)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jan 2008.
Related trials for Fevers
Recruiting
Assessment of Communication Interventions on Vaccination Knowledge and Acceptance
Vaccination Knowledge and Acceptance, Informed Vaccine-decision Making
RecruitingObservational study
Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders
Trisomy 8 Mosaicism, Trisomy 8 Associated Autoinflammatory Disease
RecruitingObservational study
Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics
Familial Mediterranean Fever (FMF), Autoinflammation
RecruitingPhase 1
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
Peritoneal Mesothelioma, Peritoneal Carcinomatosis
Recruiting
Recovery After Fatigue in Young Athletes: Comparison Between TECAR Therapy and Cycle Ergometer"
Muscle Fatigue, Healthy Adult
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael Greenwald, MD principal investigator
Children's Healthcare of Atlanta
Patrick P Mularoni, MD study director
Johns Hopkins All Children's Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Lubricant Instillation and Lidocaine Lubricant in people with Fevers and Pain, run by Children's Healthcare of Atlanta at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Jan 2008. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Modified Behavior Pain Scale (time frame: Procedure (approx. 6 minutes)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jan 2008.